Sugi Predict

Sugi Predict / Compounds / SCHEMBL352251

SCHEMBL352251

SCHEMBL352251

C=C1CCC(O)(O)CC1=CC=C1CCC[C@@]2(C)C1CC[C@@H]2[C@H](C)CCCC(C)(C)O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.75
▸ SMN1; SMN2 Q16637 2/20 0.75
▸ SREBF1 P36956 1/20 0.75
▸ VDR P11473 7/20 0.69
▸ NR1I2 O75469 1/20 0.69
▸ ABCB11 O95342 1/20 0.69
▸ GC P02774 1/20 0.69
▸ PGR P06401 1/20 0.69
▸ ADORA3 P0DMS8 1/20 0.69
▸ RXRA P19793 1/20 0.69
▸ CHRM3 P20309 1/20 0.69
▸ CNR1 P21554 1/20 0.69
▸ SLC6A2 P23975 1/20 0.69
▸ HTR2C P28335 1/20 0.69
▸ MAPK1 P28482 1/20 0.69
▸ AGTR1 P30556 1/20 0.69
▸ SLC6A4 P31645 1/20 0.69
▸ ADRA1A P35348 1/20 0.69
▸ PTGS2 P35354 1/20 0.69
▸ OPRD1 P41143 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6403771 1.00 MAPT (0.75) MAPTSMN1; SMN2SREBF1VDRNR1I2
SCHEMBL11493159 0.92 MAPT (0.64) MAPTSMN1; SMN2SREBF1VDRNR1I2
SCHEMBL6407438 0.91 MAPT (0.73) MAPTSMN1; SMN2SREBF1VDRNR1I2
SCHEMBL8934472 0.91 MAPT (0.72) MAPTSMN1; SMN2SREBF1VDRNR1I2
SCHEMBL11524819 0.90 MAPT (0.61) MAPTSMN1; SMN2SREBF1VDRNR1I2
SCHEMBL11524817 0.90 MAPT (0.61) MAPTSMN1; SMN2SREBF1VDRNR1I2
SCHEMBL8003899 0.90 MAPT (0.74) MAPTSMN1; SMN2SREBF1VDRNR1I2
SCHEMBL232217 0.90 MAPT (0.74) MAPTSMN1; SMN2SREBF1VDRNR1I2
SCHEMBL10034122 0.90 MAPT (0.74) MAPTSMN1; SMN2SREBF1VDRNR1I2
SCHEMBL10616160 0.90 MAPT (0.73) MAPTSMN1; SMN2SREBF1VDRNR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890679-A2 STEROID KIT AND FOAMABLE COMPOSITION AND USES THEREOF Foamix Ltd. (IL) 2008-02-27 — — EP claimed
WO-2007012977-A2 STEROID KIT AND FOAMABLE COMPOSITION AND USES THEREOF FOAMIX LTD (US) 2007-02-01 — — WO claimed
US-20230058146-A1 METHOD OF DIAGNOSIS, PROGNOSIS, AND TREATMENT OF VITAMIN D DEFICIENCY AND VITAMIN D IMBALANCE AND DISEASES AND DISORDERS ASSOCIATED THEREOF TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2023-02-23 — — US disclosed
EP-3317250-B1 (20S)-1ALPHA,25-DIHYDROXY-24,24-DIFLUORO-19-NOR-VITAMIN D3 ANALOGS AND THEIR PHARMACEUTICAL USES WISCONSIN ALUMNI RES FOUND (US) 2020-09-09 — — EP disclosed
EP-3317250-A1 1A,25-DIHYDROXY-24,24-DIFLUORO-19-NOR-VITAMIN D3 ANALOGS AND THEIR PHARMACEUTICAL USES Wisconsin Alumni Research Foundation (US) 2018-05-09 — — EP disclosed
EP-2934462-B1 TWO-PHASE DEVELOPER FOR OXIDATIVE COLOR CHANGING AGENTS HENKEL AG & CO KGAA (DE) 2017-11-29 — — EP disclosed
EP-2550066-B1 VISCOSITY-PRODUCING TWO PHASE DEVELOPER WITH A CLEAR OIL PHASE FOR OXIDATIVE COLOUR MODIFYING AGENTS HENKEL AG & CO KGAA (DE) 2017-06-28 — — EP disclosed
US-20160347710-A1 1-ALPHA,25-DIHYDROXY-24,24-DIFLUORO-19-NOR-VITAMIN D3 ANALOGS AND THEIR PHARMACEUTICAL USES WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2016-12-01 — — US disclosed
WO-2016191583-A1 1α,25-DIHYDROXY-24,24-DIFLUORO-19-NOR-VITAMIN D3 ANALOGS AND THEIR PHARMACEUTICAL USES WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2016-12-01 — — WO disclosed
EP-2410972-B1 TWO-PHASE DEVELOPER HENKEL AG & CO KGAA (DE) 2016-10-12 — — EP disclosed
EP-2934462-A2 TWO-PHASE DEVELOPER FOR OXIDATIVE COLOR CHANGING AGENTS Henkel AG&Co. KGAA (DE) 2015-10-28 — — EP disclosed
WO-2006108373-A1 COMPLEXES CONSISTING OF VITAMIN D-COMPOUNDS OR ANALOGUES THEREOF HAVING A 5Z,7E,10(19)-TRIENE SYSTEM AND METHYLATED DERIVATIVES OF ß-CYCLODEXTRIN BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-10-19 — — WO disclosed
EP-0910644-B1 RETINOID METABOLIZING PROTEIN UNIV KINGSTON (CA) 2005-11-09 — — EP disclosed
US-6861238-B1 Retinoid metabolizing protein QUEEN'S UNIVERSITY AT KINGSTON (CA) 2005-03-01 — — US disclosed
US-20040259074-A1 Drug screening via exposing transfected cells to drugs and analyzing expression/retinoid oxidation; oxidases, hydroxylases QUEEN'S UNIVERSITY AT KINGSTON (CA) 2004-12-23 — — US disclosed
US-20040235057-A1 Retinoid metabolizing protein QUEEN'S UNIVERSITY AT KINGSTON (CA) 2004-11-25 — — US disclosed
US-6306624-B1 NUCLEOTIDE SEQUENCES CODING PREFERENTIAL POLYPEPTIDE; FOR USE IN CONTROLLING RETINOIC ACID METABOLISM QUEEN'S UNIVERSITY AT KINGSTON (CA) 2001-10-23 — — US disclosed
US-6063606-A NUCLEOTIDE SEQUENCE THAT CODES FOR A PROTEIN THAT OXIDES A RETINOID; FOR THE TREATMENT OF CANCER; ANTICARCINOGENIC AGENTS PROVENTIV THERAPEUTICS, LLC 2000-05-16 — — US disclosed
EP-0910644-A1 RETINOID METABOLIZING PROTEIN QUEEN'S UNIVERSITY AT KINGSTON (CA) 1999-04-28 — — EP disclosed
WO-1997049815-A1 RETINOID METABOLIZING PROTEIN QUEEN'S UNIVERSITY AT KINGSTON (CA) 1997-12-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160347710-A1 1-ALPHA,25-DIHYDROXY-24,24-DIFLUORO-19-NOR-VITAMIN D3 ANALOGS AND THEIR PHARMACEUTICAL USES CYP24A1, VDR, CYP2R1 MAPT 4285/4885SMN1; SMN2 2939/4885SREBF1 362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.